AZD0754

N/A

Report date: 2025/07/01 20:00:14

Base Information

Drug NameAZD0754

Drug Alias NameAZD0754AZD-0754

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > PMBC-derived

Mechanisms of ActionSix-transmembrane epithelial antigen of the prostate 2 inhibitors

TargetsSix-transmembrane epithelial antigen of the prostate 2

Therapy Area/IndicationsProstatic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesAustraliaSpain

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesAstrazeneca Plc

China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Plc

Inactive CompaniesN/A

Active IndicationsProstatic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A